Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P1101 Extension Study in Japanese PV and ET Patients
NCT04655092Phase 3Recruiting
- Sponsor
- PharmaEssentia
- Start
- Jan 2021
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ropeginterferon alfa-2b in polycythemia vera (PV) and essential thrombocythemia (ET), sponsored by PharmaEssentia. Primary endpoint: Maintenance rate of phlebotomy-free Complete Hematologic Response at 2 years. Started Jan 2021; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT04655092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655092.